Table 3.
HDMTX course immediately following glucarpidase | All other HDMTX courses for the same patients | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Number of patients rechallenged |
Time to MTX rechallenge (days) a [median (range)] |
% of full HDMTX dosage administered at rechallenge [median (range)] |
HDMTX Dosage (g/m2) [median (range)] |
Max Scr (mg/dL) [median (range)] |
SCr % increase from baseline [median (range)] |
Time to complete MTX excretion (hrs) [median (range)] |
Total number of courses |
HDMTX Dosage (g/m2) [median (range)] |
Max Scr (mg/dL) [median (range)] |
SCr % increase from baseline [median (range)] |
Time to complete MTX excretion (hrs) [median (range)] |
|
All Patients (n = 20) |
13 | 28 (18 – 70) |
67 (50 – 100) |
2.486 (1.6 – 12) |
0.8 (0.4 – 1.6) |
25 (0 – 128.6) |
90 (66 – 268) |
26 | 8.5 (2 – 12) |
0.6 (0.4 – 0.9) |
22.5 (0 – 50) |
72 (42 – 116) |
Osteosarcoma (n = 6) |
4 | 43 (20 – 70) |
67 (50 – 100) |
8 (6 – 12) |
0.8 (0.5 – 1.6) |
42.5 (14.3 – 128.6) |
96 (72 – 268) |
13 | 12 (12 – 12) |
0.6 (0.5 – 0.9) |
25 (0 – 50) |
72 (72 – 116) |
ALL (n = 10) |
7 | 27 (18 – 32) |
67 (50 – 100) |
2.02 (1.6 – 2.714) |
0.8 (0.5 – 0.9) |
25 (0 – 100) |
90 (66 – 114) |
10 | 3.153 (2 – 5) |
0.6 (0.4 – 0.9) |
16.3 (0 – 33.3) |
66 (42 – 92) |
Other (n = 4) |
2 | 26 (23 – 29) |
80 (60 – 100) |
2.243 (2 – 2.486) |
0.8 (0.4 – 1.1) |
28.6 (0 – 57.1) |
78 (66 – 90) |
3 | 3.1 (3 – 4.5) |
0.4 (0.4 – 0.8) |
33.3 (14.3 – 33.3) |
42 (42 – 66) |
HDMTX, high-dose methotrexate; g, grams; SCr, serum creatinine; MTX, methotrexate; mg, milligram; dL, deciliter; hrs, hours; ALL, acute lymphoblastic leukemia
The time to methotrexate rechallenge was the time elapsed between the start of the HDMTX course in which glucarpidase was administered and the start of the next HDMTX infusion.